# OnCo record paper-iris-imatinib-nejm-2003 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-iris-imatinib-nejm-2003/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-iris-imatinib-nejm-2003" ;
  schema:name "IRIS: imatinib versus interferon plus cytarabine as first treatment for chronic myeloid leukaemia"@en ;
  schema:description "Imatinib beat the previous standard by a wide margin in newly diagnosed CML, and the long-term follow-up showed most patients alive at ten years."@en ;
  schema:url <https://onco.cc/key-papers/paper-iris-imatinib-nejm-2003/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa022457>, <https://doi.org/10.1056/NEJMoa1609324>, <https://clinicaltrials.gov/study/NCT00006343> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa022457> ;
  schema:datePublished "2003"^^xsd:gYear ;
  schema:author "O'Brien SG, Guilhot F, Larson RA, et al." ;
  onco:related <https://onco.cc/key-papers/paper-druker-imatinib-phase1-nejm-2001/> ;
  onco:cancers <https://onco.cc/cancers/cml/> ;
  onco:targets <https://onco.cc/targets/bcr-abl/> ;
  onco:drugs <https://onco.cc/drugs/imatinib/>, <https://onco.cc/drugs/dasatinib/>, <https://onco.cc/drugs/nilotinib/>, <https://onco.cc/drugs/asciminib/> ;
  onco:companies <https://onco.cc/companies/novartis/> ;
  onco:terms <https://onco.cc/terms/pfs/>, <https://onco.cc/terms/os/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-drug-pricing/>, <https://onco.cc/bottlenecks/b-global-access/> ;
  onco:journals <https://onco.cc/journals/nejm/> .